Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 0442)

L'Hospitalet Del Llobregat, Barcelona 08908

0 studies enrolling now · 1 studies all time

What they study most

Hematological Malignancies

Studies at this site

• A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) — Completed